Aster Capital Management’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
Other funds holding CORT
Aster Capital Management's CORT Position: Q3 2026 in Review
Aster Capital Management opened a new position in Corcept Therapeutics (CORT) in Q3 2026: 1 share worth $115. The stake represents ﹤0.01% of the portfolio and ranks #940 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in CORT as recently as Q1 2026.
Aster Capital Management first reported a position in CORT in Q4 2024 and has held it in 6 quarters since. The position peaked at $230K in Q2 2025. 503 funds tracked by Wall St. Rank hold CORT as of Q3 2026.
- Aster Capital Management held 1 share of Corcept Therapeutics worth $115 as of Q3 2026.
- Corcept Therapeutics was a new Aster Capital Management position in Q3 2026.
- Corcept Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q3 2026, its #940 holding.
- Aster Capital Management first reported a position in Corcept Therapeutics in Q4 2024 and has held it in 6 quarters since.
- Aster Capital Management's Corcept Therapeutics position peaked at $230K in Q2 2025.
- 503 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.
Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.